Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Prostate Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00653757 |
Recruitment Status :
Completed
First Posted : April 7, 2008
Last Update Posted : March 19, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Using scintigraphy to plan specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
PURPOSE: This phase I/II trial is studying the side effects and best way to give intensity-modulated radiation therapy and to see how well it works in treating patients with stage I, stage II, stage III, or stage IV prostate cancer.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Prostate Cancer | Drug: goserelin acetate Drug: leuprolide acetate Radiation: image-guided radiation therapy Radiation: intensity-modulated radiation therapy | Phase 1 Phase 2 |
OBJECTIVES:
- To assess the feasibility of radioimmunoguided intensity-modulated radiotherapy (IMRT) for stage I-IV prostate cancer.
- To determine the toxicity and tolerance of this regimen in these patients.
- To determine the tumor response based on physical examination and serial measurements of the serum prostate-specific antigen (PSA) levels in these patients.
- To determine the outcome of patients treated on this study with radioimmunoguided IMRT compared to 2 control groups of patients treated at Mayo Scottsdale Clinic (MSC).
OUTLINE: Patients undergo radioimmunoguided intensity-modulated radiotherapy once daily, 5 days a week for 8½ weeks. Beginning the last week of radiotherapy, some patients receive leuprolide acetate intramuscularly every 3-4 months or goserelin subcutaneously every 3 months for 6 months, 12 months, or until disease progression.
After completion of study treatment, patients are followed every 3-4 months for 1 year, every 6 months for 4 years and annually thereafter
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase I/II Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer |
Study Start Date : | March 2002 |
Actual Primary Completion Date : | December 2006 |
Actual Study Completion Date : | December 2007 |

- Toxicity
- Survival rates
- Freedom from biochemical relapse rates
- Local control rates
- Distant failure rates
- Biochemical freedom from failure rates
- Comparison of outcomes to patients treated with conventional radiotherapy and intensity-modulated radiotherapy without radioimmunoguidance
- Obstructive urinary symptoms
- Sexual health as assessed by inventory questionnaire

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
-
Pathologically confirmed prostate cancer
- Stage I-IV disease (T1-4, N0-1, M0)
- No evidence of distant metastases (M0) on physical examination or bone scan
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Hemoglobin ≥ 10.0 g/dL
- WBC ≥ 3,000/mcL
- Platelet count ≥ 90,000/mm
- AST < 2 times the upper limit of normal
- No allergy to leuprolide acetate or goserelin
PRIOR CONCURRENT THERAPY:
- Not specified

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00653757
United States, Arizona | |
Mayo Clinic in Arizona | |
Scottsdale, Arizona, United States |
Study Chair: | Steven E. Schild, M.D. | Mayo Clinic |
Responsible Party: | Steven E Schild, M.D., Mayo Clinic Cancer Center |
ClinicalTrials.gov Identifier: | NCT00653757 |
Other Study ID Numbers: |
CDR0000588847 P30CA015083 ( U.S. NIH Grant/Contract ) 390-02 ( Other Identifier: Mayo Clinic Cancer Center ) 390-02 ( Other Identifier: Mayo Clinic IRB ) |
First Posted: | April 7, 2008 Key Record Dates |
Last Update Posted: | March 19, 2012 |
Last Verified: | March 2012 |
stage I prostate cancer stage II prostate cancer stage III prostate cancer stage IV prostate cancer |
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Prostatic Diseases Leuprolide |
Goserelin Fertility Agents, Female Fertility Agents Reproductive Control Agents Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents |